The market was just a little weak this morning and biotechs responded as one would expect, although despite the sea of red I kept thinking that it could be have been worse. Today was certainly not a good day but the market is starting to provide us some good bargains. There could be a larger […]
January 27 Biotech Update
It is amazing how quickly sentiment can change. Last week I was noting the shifts and the expectations for a correction. This was certainly needed but I think the speed of the move has less to do with fundamentals and more to do with jittery investors. Nobody wants to be the last one to sell, […]
January 22nd Biotech Update
I feel like a record stuck skipping over the same part but there has not really been anything new in the market this week either from a macro sense or even at the individual level. The sector was strong in the morning basically on the backs of the large caps (see GILD later in the […]
January 21st Biotech Update on GILD ECYT ONTX
The sector is looking a little tired at these levels but it seems like everyone is expecting a pullback, which makes the contrarian in me wonder if there is another leg higher. I am certainly not selling anything at this point but would be cautious about buying now. I would not be surprised to see catalyst stocks […]
January 17 Biotech Update- Building a Diagnostic Foundation
Today was more of the same in the sector and that is generally positive given the sentiment. I know it seems like biotech has been going up every day (we have certainly had a good run recently) but it seems to me like this is the only sector that is not warning on earnings as […]
Analysis of TGR-1202, a PI3K Delta Inhibitor From TGTX
This is a quick take on the TGTX efficacy data presented at ASH this past weekend. TG Therapeutics reported PK data as well as results from the higher 800 mg cohort. It appears this step up from 400 mg has finally resulted in some activity and the company continues to dose escalate; an 1800 mg […]
December 2 Biotech Update- Getting Ready for ASH
Last week ended well for biotechs and today was a little more of the same with perhaps some consolidation. News has been relatively limited as most traders/investors/general biotech followers are gearing up for ASH. I will be heading down on Friday and staying through Tuesday, which means there will not be any updates this Friday, […]
November 22 Biotech Update- A Busy CHMP out with some Bullish News
You will notice that I am change the title to something more descriptive, hopefully you will still read the updates with this change. Sentiment is certainly shifting in the biotech sector and it seems to be doing so as quickly as it turned negative. What was my fear that the sector would be hit with […]
November 18-EOD
Thankfully there was not a lot of news but biotechs did not just drift lower. I still worry about tax loss selling hitting the sector (or at least the small to mid caps) heading into the end of the year but it is nice to see that the sector can tread water on no news […]
ASH 2013 Preview on Myelofibrosis
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs on the backs of Pharmacyclic’s Ibrutinib (stock is up 1000% since ASH11), Celgene’s Revlimid (~67% of their $6.3B 2013 revenue) and Amgen’s $10.6B deal for […]
ASH 2013 Preview on Lymphoid Malignancies
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking the biotech sector’s run the past 2 years. They are now within months of receiving approval for 2 indications where they could benefit patient lives […]
November 5- EOD
The morning looked bad but the sector came back a little. There was some sporadic buying of oncology names but nothing major. It will be very interesting to see how the sector responds to the ASH abstracts. Obviously there will be winners and losers but the question in my mind is how will the PPS […]
October 29- EOD
Well, it seemed like an odd day for the sector in that it was almost directionless. This is not to say that there were not moves among individual stocks but we are finally starting to see them move on merit and less on sector sentiment. I think this is a good sign and hopefully we […]
October 10-EOD
Macro, macro, macro but now it is to the other way. We did have another big piece of news hit last night in terms of CLL, which I will talk about for today’s note. 1. The news of the day (or actually last night) was the halting of the GILD idelalisib trial of previously treated […]
Quick comments on Achillion and TG Therapeutics
(with Jason Chew) In biotech, all too often are investors given news on Friday that is not so good. With many updates expected by the end of the quarter, someone was bound to have the honors of being one of those companies. Today we had quite bad news out of Achillion and an update from […]
What to look for at AASLD 2013
We wanted to take a moment to highlight some of the presentations at the 2013 Annual Meeting of the American Association for the Study of Liver Diseases. This conference takes place Friday, November 1st thru Tuesday, November 5th and covers . Research interest in new therapies against the hepatitis C virus(HCV) still remain high, although […]
July 26-EOD
It was a relatively quiet day on the news front outside of the hep-C space where there as some news on both VRTX and GILD. Not much happening in the afternoon, so wrapping it up a little early. 1. VRTX announced that the FDA put a clinical hold on their all oral trial using VX-135. […]
July 22- EOD
It is more of the same in that the market is a little quiet on news. I expected that there would be something interesting to talk about today but not so much. That being said there are a couple of items that I think might be important to note. 1. There has been a lot […]
July 16- EOD
Seemed like a slow news day as the markets pulled back to consolidate some of the recent moves. Biotechs were not immune to the move, although some clearly performed better than others. 1. EPZM has shown incredible strength since the IPO. While I like this company’s technology and would like to own some shares, it […]
INFI – Infinity Pharma, Staying The Course
This has been one heck of a roller-coaster ride. The stock took 8 months to triple in price, and just 2 to give it all back. Shares began to swoon prior to data presentations at ASCO and ICML. We had expected positive results to soothe the market, but this was not the case. Investors focused […]
